Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 12;8:1443–1449. doi: 10.2147/OTT.S84467

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Xing et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

CpG-ODN 7909 presented significant radiation-enhancing effects on H460R cells.

Notes: Combined treatment with IR and CpG-ODN 7909 contributed to further reduction in the survival fractions at each dose tested compared to IR alone (*P<0.05 vs IR group at each dose tested). The dose–survival curve of H460R cells treated with CpG-ODN 7909 plus IR exhibited a narrow shoulder (indicating decrease in Dq) and a greater slope rate (indicating decrease in D0), indicating that CpG-ODN 7909 enhanced radiosensitivity when combined with IR treatment. However, the radiation-enhancing effects disappeared after TLR9 activation was blocked by CQ.

Abbreviations: CpG-ODN 7909, CpG oligodeoxyribonucleotide 7909; H460R, radioresistant H460; IR, irradiation; TLR9, toll-like receptor 9; CQ, chloroquine.